A blockbuster breast cancer niche has Roche and Sanofi in the lead

A blockbuster breast cancer niche has Roche and Sanofi in the lead

SABCS: Pfizer’s Ibrance backs up benefit in HER2-negative breast cancer with real-world data

SABCS: Pfizer's Ibrance backs up benefit in HER2-negative breast cancer with real-world data

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

Clinical Catch-Up for the First Week of July

Clinical Catch-Up for the First Week of July

Move aside, Humira. Merck’s Keytruda will capture industry’s top sales spot in 2024: report

Move aside, Humira. Merck's Keytruda will capture industry's top sales spot in 2024: report

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years